My IDSA Contact Us
IDSA NewsPrint-Friendly Newsletter
Forward to a Friend
Search Back Issues
 
Education & Training Resources Practice Guidlines Journals & Publications Policy & Advocacy Meetings About IDSA
May 1, 2008
FDA Lowers Vancomycin Breakpoints for Staph Infections
The Food and Drug Administration (FDA) has lowered the breakpoints for vancomycin in the treatment of Staphylococcus aureus to reflect growing rates of resistance, and in response to urging from IDSA and others. 
WHO Reports Progress on Dracunculiasis Eradication
The end is in sight for the global campaign to eradicate dracunculiasis (guinea-worm disease), but daunting challenges still remain in endemic areas of Mali and Sudan, according to the World Health Organization. 
IDSA Literature Review - April 2008
In this new feature, a panel of IDSA members identifies and critiques important new infectious diseases studies in the current literature that have a significant impact on the practice of infectious diseases medicine.
Brazil Has Large Dengue Fever Outbreak
Malaria Reported in Bahamas
Polio Eradication Update: Cases Down Overall, But Type 3 Cases Up
Rift Valley Fever Outbreak in Madagascar
Vietnam Reports Cholera Outbreak
Yellow Fever Reported in Liberia, Argentina
Cefixime Available Again in the United States
Drug Approvals, Recalls, Adverse Events Update
In the IDSA Journals
From the President
IDSA Endorses Two Vaccine Financing Bills
IDSA Urges FDA to Dedicate Resources to Antimicrobial Resistance
Members on the Move
Welcome, New IDSA Members!
FDA Lowers Vancomycin Breakpoints for Staph Infections
WHO Reports Progress on Dracunculiasis Eradication
IDSA Literature Review - April 2008
Brazil Has Large Dengue Fever Outbreak
Malaria Reported in Bahamas
Polio Eradication Update: Cases Down Overall, But Type 3 Cases Up
Rift Valley Fever Outbreak in Madagascar
Vietnam Reports Cholera Outbreak
Yellow Fever Reported in Liberia, Argentina
Cefixime Available Again in the United States
Drug Approvals, Recalls, Adverse Events Update
In the IDSA Journals
From the President
IDSA Endorses Two Vaccine Financing Bills
IDSA Urges FDA to Dedicate Resources to Antimicrobial Resistance
Members on the Move
Welcome, New IDSA Members!
IDSA | 1300 Wilson Blvd., Suite 300 | Arlington, VA 22209 | Phone: (703) 299-0200
To ensure delivery, please add 'idsa@idsociety.org' to your email address book or Safe Sender List.
If you are still having problems receiving our communications,
see our white-listing page for more details.

Unsubscribe here